Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06108063
PHASE1/PHASE2

Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan

Sponsor: Steadman Philippon Research Institute

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the efficacy of Losartan use post-operatively for reducing or preventing the development of arthrofibrosis and the associated adverse impacts on clinical outcomes.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2024-03-06

Completion Date

2027-06-30

Last Updated

2024-03-12

Healthy Volunteers

No

Interventions

DRUG

Losartan

12.5 mg oral Losartan taken for 28 days total (4 week postoperative).

DRUG

Placebo - Losartan

Losartan appearance-matched Prosolv EasyTab SP placebo. 12.5 mg oral tablet taken for 28 days total (4 week postoperative).

Locations (1)

The Steadman Clinic

Vail, Colorado, United States